SAFETY DATA SHEETS

This SDS packet was issued with item:

078924375

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078924376

According to EC Regulation 1907/2006 (REACH)



PRODUCT SAFETY DATA SHEET

VETAMEG INJECTION (FLUNIXIN MEGLUMINE)

1. IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF COMPANY / UNDERTAKING

Product Name Vetameg Injection

Supplier Aspen Veterinary Resources LTD.

3155 Heartland Liberty, MO 64068 Phone: 816 415 4324

Fax: 816 415 4314

Manufactured By Norbrook Laboratories Ltd,

Station Works, Newry, Co.Down,

N.Ireland, BT35 6JP.

2. HAZARDS IDENTIFICATION

Physical and Chemical Hazards : Not classified as dangerous under EEC Directives 67/548/EEC,

88/379/EEC or 99/45/EC.

Environmental Hazards : None known

Adverse Human Health Effects : There are no known adverse effects of exposure to Vetameg.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Substance/Preparation : Preparation Active
Ingredients : Flunixin Meglumine

Description : Non-narcotic, non-steroidal analgesic

Chemical Family : Flunixin - non-steroidal, anti-inflammatory drug (NSAID)

4. FIRST AID MEASURES

Inhalation : Remove to fresh air. If any signs or symptoms occur or persist seek medical advice.

Skin Contact : Wash thoroughly with soap and water. Remove contaminated clothing and wash before

reuse.

Eyes Contact : Immediately flush eyes with copious amounts of water for at least 15 minutes. If irritation

persists, seek medical attention.

Ingestion : Do not induce vomiting. Seek medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing media: Use carbon dioxide, dry chemical or alcohol-resistant foam spray extinguishers.

Use water spray to cool fire-exposed containers. A fine water mist may be used

to smother or to disperse vapors.

Fire and explosion hazards: None

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions : Provide good ventilation. Prevent skin and eye contact.

Environmental Precautions: Keep away from drains, surface-water, ground-water and soil.

Method for Clean-up : Absorb small spills on spill pillows, sand, sawdust or other suitable absorbing

material.

7. HANDLING AND STORAGE

Handling : Avoid contact with eyes, skin or clothing. Do not breathe vapours or mist. Do not ingest.

Do not smoke or eat while handling the product. Wash thoroughly after handling. The

containers should be stored in their original boxes when not in use.

Storage : Store in closed containers in a cool, dry, well-ventilated area, between 2°C and 30°C and

away from oxidisers, heat, sparks and open flame. Protect containers from physical damage

and light.

Keep container closed when not in use. Do not transfer contents to unlabeled containers. Use only with adequate ventilation. Keep out of reach of children. Should any discoloration

occur, the product should be discarded.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Component - Occupational Exposure Standard

Flunixin Not Established

For pure flunixin meglumine:

LD50 (Oral, rat): 120 mg/kg

Protective Equipment : Wear vinyl, nitrile or rubber gloves, a waterproof bib-apron and suitable eye

protection when applying the product.

9. PHYSICAL AND CHEMICAL PROPERTIES

Form : Liquid

Color : Clear, colorless

Odor : None.

10. STABILITY AND REACTIVITY

Stability : Stable under normal temperatures and pressures.

Conditions to avoid : None known

Materials to avoid : None known

11. TOXICOLOGICAL INFORMATION

Exposure Effects (Acute)

Eye Contact : Direct contact of the solution with eyes can cause irritation.

Skin Contact : Prolonged or repeated contact with Vetameg may cause irritation and/or drying

and cracking of the skin.

REVISION DATE: 170/05/13

Inhalation : None known.

Ingestion : Oral toxicity of the Vetameg solution is low.

Exposure Effects (Chronic)

Unknown for the product mixture. When this product is used according to the directions, prolonged exposure of man is not expected. Both its mutagenicity

and its teratogenicity are not known.

12. ECOLOGICAL INFORMATION

Data on the ecological implications for Vetameg is not yet available.

13. DISPOSAL CONSIDERATIONS

Product/Residues : Do not discharge the product material into surface or waste water. For

disposal, use an incinerator licensed for chemical waste.

Package : Dispose of waste containers using regular disposal methods in accordance

with local and national environmental regulations.

14. TRANSPORT INFORMATION

Land, Sea & Air Transport

ADR/RID, IMO/IMDG, IATA/ICAO, UN No. : Not applicable

15. REGULATORY INFORMATION

Labelling Information : None

Safety phrases : S2 Keep out of reach of children

S7 Keep container tightly closed

16. OTHER INFORMATION

For Animal Treatment Only Injectable solution 50mg/mL

ANADA 200-476, approved by FDA

Revision Date : 17/05/13

Revision No : 01

Printing Date : 17/05/2013

Suppliers data sheets and various chemicals and pharmaceuticals databases were used to compile this sheet.

The information contained in this PSDS is believed to be accurate and represents the best information available at the time of preparation. However Norbrook Laboratories Limited makes no warranty, express or implied, with respect to such information and assumes no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes, and Norbrook Laboratories Limited will not be held liable for any damage resulting from the handling of or contact with the above product.

According to EC Regulation 1907/2006 (REACH)



PRODUCT SAFETY DATA SHEET

VETAMEG INJECTION (FLUNIXIN MEGLUMINE)

1. IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF COMPANY / UNDERTAKING

Product Name Vetameg Injection

Supplier Aspen Veterinary Resources LTD.

3155 Heartland Liberty, MO 64068 Phone: 816 415 4324

Fax: 816 415 4314

Manufactured By Norbrook Laboratories Ltd,

Station Works, Newry, Co.Down,

N.Ireland, BT35 6JP.

2. HAZARDS IDENTIFICATION

Physical and Chemical Hazards : Not classified as dangerous under EEC Directives 67/548/EEC,

88/379/EEC or 99/45/EC.

Environmental Hazards : None known

Adverse Human Health Effects : There are no known adverse effects of exposure to Vetameg.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Substance/Preparation : Preparation Active
Ingredients : Flunixin Meglumine

Description : Non-narcotic, non-steroidal analgesic

Chemical Family : Flunixin - non-steroidal, anti-inflammatory drug (NSAID)

4. FIRST AID MEASURES

Inhalation : Remove to fresh air. If any signs or symptoms occur or persist seek medical advice.

Skin Contact : Wash thoroughly with soap and water. Remove contaminated clothing and wash before

reuse.

Eyes Contact : Immediately flush eyes with copious amounts of water for at least 15 minutes. If irritation

persists, seek medical attention.

Ingestion : Do not induce vomiting. Seek medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing media: Use carbon dioxide, dry chemical or alcohol-resistant foam spray extinguishers.

Use water spray to cool fire-exposed containers. A fine water mist may be used

to smother or to disperse vapors.

Fire and explosion hazards: None

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions : Provide good ventilation. Prevent skin and eye contact.

Environmental Precautions: Keep away from drains, surface-water, ground-water and soil.

Method for Clean-up : Absorb small spills on spill pillows, sand, sawdust or other suitable absorbing

material.

7. HANDLING AND STORAGE

Handling : Avoid contact with eyes, skin or clothing. Do not breathe vapours or mist. Do not ingest.

Do not smoke or eat while handling the product. Wash thoroughly after handling. The

containers should be stored in their original boxes when not in use.

Storage : Store in closed containers in a cool, dry, well-ventilated area, between 2°C and 30°C and

away from oxidisers, heat, sparks and open flame. Protect containers from physical damage

and light.

Keep container closed when not in use. Do not transfer contents to unlabeled containers. Use only with adequate ventilation. Keep out of reach of children. Should any discoloration

occur, the product should be discarded.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Component - Occupational Exposure Standard

Flunixin Not Established

For pure flunixin meglumine:

LD50 (Oral, rat): 120 mg/kg

Protective Equipment : Wear vinyl, nitrile or rubber gloves, a waterproof bib-apron and suitable eye

protection when applying the product.

9. PHYSICAL AND CHEMICAL PROPERTIES

Form : Liquid

Color : Clear, colorless

Odor : None.

10. STABILITY AND REACTIVITY

Stability : Stable under normal temperatures and pressures.

Conditions to avoid : None known

Materials to avoid : None known

11. TOXICOLOGICAL INFORMATION

Exposure Effects (Acute)

Eye Contact : Direct contact of the solution with eyes can cause irritation.

Skin Contact : Prolonged or repeated contact with Vetameg may cause irritation and/or drying

and cracking of the skin.

ANADA 200-476 - VETAMEG(FLUNIXIN MEGLUMINE)

REVISION DATE: 170/05/13

Inhalation : None known.

Ingestion : Oral toxicity of the Vetameg solution is low.

Exposure Effects (Chronic)

Unknown for the product mixture. When this product is used according to the directions, prolonged exposure of man is not expected. Both its mutagenicity

and its teratogenicity are not known.

12. ECOLOGICAL INFORMATION

Data on the ecological implications for Vetameg is not yet available.

13. DISPOSAL CONSIDERATIONS

Product/Residues : Do not discharge the product material into surface or waste water. For

disposal, use an incinerator licensed for chemical waste.

Package : Dispose of waste containers using regular disposal methods in accordance

with local and national environmental regulations.

14. TRANSPORT INFORMATION

Land, Sea & Air Transport

ADR/RID, IMO/IMDG, IATA/ICAO, UN No. : Not applicable

15. REGULATORY INFORMATION

Labelling Information : None

Safety phrases : S2 Keep out of reach of children

S7 Keep container tightly closed

16. OTHER INFORMATION

For Animal Treatment Only Injectable solution 50mg/mL

ANADA 200-476, approved by FDA

Revision Date : 17/05/13

Revision No : 01

Printing Date : 17/05/2013

Suppliers data sheets and various chemicals and pharmaceuticals databases were used to compile this sheet.

The information contained in this PSDS is believed to be accurate and represents the best information available at the time of preparation. However Norbrook Laboratories Limited makes no warranty, express or implied, with respect to such information and assumes no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes, and Norbrook Laboratories Limited will not be held liable for any damage resulting from the handling of or contact with the above product.